Am­gen re­ports more Up­liz­na da­ta in myas­the­nia gravis ahead of FDA fil­ing

Am­gen has shared ad­di­tion­al Phase 3 da­ta for its rare dis­ease drug Up­liz­na in myas­the­nia gravis, bol­ster­ing the com­pa­ny’s case for la­bel ex­pan­sion be­fore a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER